1. At a Glance – Small Cap, Big Cough Syrup Energy
₹153 crore market cap. ₹133 share price. 6.31% return in 3 months. Stock P/E of 11.4 when industry median is 28+. ROE at 15.1%, ROCE 14%, EV/EBITDA 7.04. Debt ₹68.9 crore. Promoters hold 72.3%.
And then comes the mic drop: Q3 FY26 sales up 56.5% YoY and profit up 201% YoY.
Yes, you read that correctly. Not 20%. Not 30%. Two hundred and one percent.
While big pharma giants are busy fighting USFDA inspections and price erosion drama, this Silvassa-based contract manufacturer quietly posted ₹62.94 crore quarterly revenue and ₹2.71 crore net profit.
But before we start dreaming of cough syrup rivers flowing into shareholder pockets — let’s breathe.
This is a small-cap pharma exporter with:
- Zero dividend payout
- 9.41% pledged shares
- Debt-to-equity of 0.77
- Current ratio of 0.86 (translation: tight liquidity)
So the question is simple:
Is this a genuine growth turnaround?
Or just one strong quarter wearing a lab coat?
Let’s open the prescription file.
2. Introduction – From Silvassa With Syrup
Incorporated in 1985, Parnax Lab Ltd manufactures and exports pharmaceutical formulations. That’s the polite way of saying — they make cough syrups, tablets, creams, gels, balms and anything that can be squeezed into a tube or bottle.
They are part of the Naxpar Group and operate a WHO-approved, EHS-compliant manufacturing facility in Silvassa.
Their real game? Contract manufacturing.
Which means they manufacture products for bigger brands. If pharma is Bollywood, Parnax is the ghost singer — you don’t see them on screen, but the song still earns.
They supply to:
- Himalaya
- L’Oreal
- Sun Pharma
- Cipla
- Dabur
- Wockhardt
- Ranbaxy
That client list alone tells you something: they’re not amateurs mixing chemicals in a garage.
But contract manufacturing is a tricky business:
- Margins are limited.
- Clients have bargaining power.
- Scale matters.
- Working capital matters even more.
And guess what? Their working capital days are negative in recent years. That’s interesting. We’ll get there.
Also — in 2022 they:
- Increased authorised capital to ₹13 crore
- Issued warrants to promoter group worth ₹12.96 crore
- Converted 16.7 lakh shares
Capital restructuring alert. Always worth noting.
Now the real question:
Is this a stable contract manufacturer compounding slowly?
Or a turnaround story trying to impress the market?
Let’s dissect.
3. Business Model – WTF Do They Even Do?
Let’s simplify this like explaining to your cousin who thinks pharma stocks only make paracetamol.
Parnax does four main things:
1️ Pharmaceuticals
Liquid products, ointments, tablets, capsules.
Specialty: High-volume oral formulations like:
